

## Blazing a New Path: An Innovative Approach to Screening Subjects

### BACKGROUND

The pathophysiological process of Alzheimer's Disease begins more than a decade before the clinical stage, now recognized as Alzheimer's Disease dementia. In this stage, individuals have preserved cognitive abilities, but underlying Alzheimer's Disease pathophysiology, known as preclinical Alzheimer's Disease. Consensus in the field is that compounds targeting the underlying disease process may have greater benefit when started earlier in the disease continuum, but no treatments that target the underlying pathology of Alzheimer's Disease in the pre-clinical stage are currently available.

### SITUATION

This Phase 3, adult participants, clinical trial is focused on pre-clinical Alzheimer's Disease and requires an intravenous infusion every four weeks for approximately 32 weeks during the double-blind treatment period. Next, there is a double-blind observation period for up to 150 weeks followed by an open-label extension period for participants who received placebo that will last 48 weeks. Pre-clinical Alzheimer's Disease can be characterized by identifying specific levels of biomarkers that indicate a predisposition for neurodegeneration in the future. Due to the high-screen failure rate for this trial, recruitment and screening of potential participants was made possible by utilizing Mobile Research Unit (MRUs) to screen large volumes of participants at community events.

### DEPLOYING MOBILE RESEARCH UNITS

PCM Trials was selected as the mobile research visit provider for the screening visit to staff MRUs. MRUs are a new concept for decentralized clinical trials and increase the geographical reach and diversity of participants who can be included in this clinical trial. The MRUs travel to events such as Community Health Fairs and Senior Expositions that target the study population and promote prevention at the community level.

PCM Trials Nurses are trained on educating and greeting potential participants as well as completing all screening visit procedures such as lab draws. PCM Trials partners with research sites to plan the logistics for Community Screening Events which has increased collaboration in the community and brings awareness of Alzheimer's Disease and clinical trials. PCM Trials Nurses are dedicated to improving the patient experience and implementing Community Screening Events to increase convenience for patients.

#### NUMBER OF MRU EVENTS

26

#### SITES

12

#### NUMBER OF U.S. STATES

6

#### PARTICIPANT SCREENED AT MRU EVENTS

231 in 9 months

**PLANNING A FUTURE TRIAL? In-home visits for clinical trials are no longer just an option—they are essential. Contact us today at [info@pcmtrials.com](mailto:info@pcmtrials.com) and [+1.303.253.7470](tel:+1.303.253.7470).**